
Last updated: 2026-10-08 21:41:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
XORTX Therapeutics Inc. (XRTX) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $1.84, with a market capitalisation of $3.14M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.59 to $7.05. This page covers its latest market performance, valuation, price trends and company information.
$3.14M | |
$1.75 | |
$1,513.35 | |
$1.59 | |
$1.75 | |
16.17K | |
229.42K | |
-- | |
$7.05 | |
$1.59 | |
-- | |
-- |
XORTX Therapeutics Inc. (XRTX) is trading at $2.22 in after-hours trading as of 2026-10-08 21:39:00, up 27.28% ($0.48) from the regular-session close of $1.75.
After-hours trading shows how investors are pricing XRTX after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, XORTX Therapeutics Inc. (XRTX) moved from $1.70 to $1.84, representing a gain of 8.18% ($0.14).
The stock traded between $1.69 and $1.84 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 27.96 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 4.6%
XRTX is currently trading at $1.84, placing it 4.6% of the way from its 52-week low of $1.59 to its 52-week high of $7.05. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
| Employees | 3 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of XORTX Therapeutics Inc. (XRTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.